Triplet Therapeutics is a biotechnology company developing transformational treatments for patients with repeat expansion disorders (REDs) -- a group of more than 50 known genetic diseases including Huntington’s disease, myotonic dystrophy, spinocerebellar ataxias, fragile X syndrome, and familial amyotrophic lateral sclerosis (ALS) -- leveraging insights from patient genetics. Triplet designs and develops potential therapeutics for REDs using its proprietary thRED Engine, which enables the Company to develop a single oligonucleotide targeting the DNA Damage Response (DDR) pathway to potentially treat multiple REDs. Triplet is backed by investments from Atlas Venture, MPM Capital and Pfizer Ventures, along with Invus, Partners Innovation Fund and Alexandria Venture Investments.
Location: United States, Massachusetts, Cambridge
Employees: 201-500
Total raised: $59M
Founded date: 2019
Investors 1
| Date | Name | Website |
| - | Atlas Vent... | atlasventu... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 17.12.2019 | - | $59M | - |
Mentions in press and media 5
| Date | Title | Description |
| 17.12.2019 | Triplet Therapeutics Launches with $59M In Financing | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Triplet Therapeutics, Inc., a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, launched today with $59 million in financing including a ... |
| 17.12.2019 | Biotechnology Company Triplet Therapeutics Raises $59 Million | Triplet Therapeutics, a biotechnology company harnessing human genetics to develop treatments for repeat expansion disorders at their source, announced it raised $59 million Triplet Therapeutics — a biotechnology company harnessing human ge... |
| 17.12.2019 | Biotech startup Triplet Therapeutics launches with $59M to harness human genetics to develop treatments for repeat expansion disorders | Triplet Therapeutics, a biotechnology startup harnessing human genetics to develop treatments for repeat expansion disorders at their source, officially launched today with $59 million in financing including a $49 million Series A financing... |
| 17.12.2019 | Triplet Therapeutics Raises $59M in Financing | Triplet Therapeutics, Inc., a Cambridge, Mass.-based biotechnology company leveraging human genetics to develop treatments for repeat expansion disorders at their source, raised $59m in financing. This includes a $49m Series A financing led... |
| 17.12.2019 | Triplet Therapeutics launches with $59M, Nessan Bermingham at the wheel | Triplet Therapeutics CEO Nessan Bermingham, Ph.D. For someone who thought he’d retire after giving up the reins at Intellia, Nessan Bermingham, Ph.D., is a busy guy. Just two months after launching Korro Bio, he’s unveiling a new biotech, T... |